Jessica A Alvarez1, Elizabeth Y Chong2, Douglas I Walker3, Joshua D Chandler4, Ellen S Michalski5, Ruth E Grossmann6, Karan Uppal3, Shuzhao Li3, Jennifer K Frediani5, Rabindra Tirouvanziam7, ViLinh T Tran3, Vin Tangpricha8, Dean P Jones3, Thomas R Ziegler8. 1. Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA. Electronic address: jessica.alvarez@emory.edu. 2. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 3. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 4. Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA; Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 5. Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Nutrition and Health Sciences Graduate Program, Laney Graduate School, Emory University, Atlanta, GA, USA. 6. College of Nursing, The University of Iowa, Ames, IA, USA. 7. Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA; Division of Pulmonary, Allergy & Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. 8. Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA; Section of Endocrinology, Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA.
Abstract
BACKGROUND: Cystic fibrosis (CF) is a chronic catabolic disease often requiring hospitalization for acute episodes of worsening pulmonary exacerbations. Limited data suggest that vitamin D may have beneficial clinical effects, but the impact of vitamin D on systemic metabolism in this setting is unknown. OBJECTIVE: We used high-resolution metabolomics (HRM) to assess the impact of baseline vitamin D status and high-dose vitamin D3 administration on systemic metabolism in adults with CF with an acute pulmonary exacerbation. DESIGN:Twenty-five hospitalized adults with CF were enrolled in a randomized trial of high-dose vitamin D3 (250,000IU vitamin D3 bolus) versus placebo. Age-matched healthy subjects served as a reference group for baseline comparisons. Plasma was analyzed with liquid chromatography/ultra-high resolution mass spectrometry. Using recent HRM bioinformatics and metabolic pathway enrichment methods, we examined associations with baseline vitamin D status (sufficient vs. deficient per serum 25-hydroxyvitamin D concentrations) and the 7-day response to vitamin D3 supplementation. RESULTS:Several amino acids and lipid metabolites differed between CF and healthy control subjects, indicative of an overall catabolic state. In CF subjects, 343 metabolites differed (P<0.05) by baseline vitamin D status and were enriched within 7 metabolic pathways including fatty acid, amino acid, and carbohydrate metabolism. A total of 316 metabolites, which showed enrichment for 15 metabolic pathways-predominantly representing amino acid pathways-differed between the vitamin D3- and placebo-treated CF subjects over time (P<0.05). In the placebo group, several tricarboxylic acid cycle intermediates increased while several amino acid-related metabolites decreased; in contrast, little change in these metabolites occurred with vitamin D3 treatment. CONCLUSIONS: Numerous metabolic pathways detected by HRM varied in association with vitamin D status and high-dose vitamin D3 supplementation in adults with CF experiencing a pulmonary exacerbation. Overall, these pilot data suggest an anti-catabolic effect of high-dose vitamin D3 in this clinical setting.
RCT Entities:
BACKGROUND:Cystic fibrosis (CF) is a chronic catabolic disease often requiring hospitalization for acute episodes of worsening pulmonary exacerbations. Limited data suggest that vitamin D may have beneficial clinical effects, but the impact of vitamin D on systemic metabolism in this setting is unknown. OBJECTIVE: We used high-resolution metabolomics (HRM) to assess the impact of baseline vitamin D status and high-dose vitamin D3 administration on systemic metabolism in adults with CF with an acute pulmonary exacerbation. DESIGN: Twenty-five hospitalized adults with CF were enrolled in a randomized trial of high-dose vitamin D3 (250,000IU vitamin D3 bolus) versus placebo. Age-matched healthy subjects served as a reference group for baseline comparisons. Plasma was analyzed with liquid chromatography/ultra-high resolution mass spectrometry. Using recent HRM bioinformatics and metabolic pathway enrichment methods, we examined associations with baseline vitamin D status (sufficient vs. deficient per serum 25-hydroxyvitamin D concentrations) and the 7-day response to vitamin D3 supplementation. RESULTS: Several amino acids and lipid metabolites differed between CF and healthy control subjects, indicative of an overall catabolic state. In CF subjects, 343 metabolites differed (P<0.05) by baseline vitamin D status and were enriched within 7 metabolic pathways including fatty acid, amino acid, and carbohydrate metabolism. A total of 316 metabolites, which showed enrichment for 15 metabolic pathways-predominantly representing amino acid pathways-differed between the vitamin D3- and placebo-treated CF subjects over time (P<0.05). In the placebo group, several tricarboxylic acid cycle intermediates increased while several amino acid-related metabolites decreased; in contrast, little change in these metabolites occurred with vitamin D3 treatment. CONCLUSIONS: Numerous metabolic pathways detected by HRM varied in association with vitamin D status and high-dose vitamin D3 supplementation in adults with CF experiencing a pulmonary exacerbation. Overall, these pilot data suggest an anti-catabolic effect of high-dose vitamin D3 in this clinical setting.
Authors: Julia L Finkelstein; Eva K Pressman; Elizabeth M Cooper; Tera R Kent; Haim Y Bar; Kimberly O O'Brien Journal: Reprod Sci Date: 2014-11-02 Impact factor: 3.060
Authors: V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Judith Grothe; Joachim Riethmüller; Sandra M Tschürtz; Marco Raith; Chris J Pynn; Dieter Stoll; Wolfgang Bernhard Journal: Cell Physiol Biochem Date: 2015-03-12
Authors: Karen W Phinney; Guillaume Ballihaut; Mary Bedner; Brandi S Benford; Johanna E Camara; Steven J Christopher; W Clay Davis; Nathan G Dodder; Gauthier Eppe; Brian E Lang; Stephen E Long; Mark S Lowenthal; Elizabeth A McGaw; Karen E Murphy; Bryant C Nelson; Jocelyn L Prendergast; Jessica L Reiner; Catherine A Rimmer; Lane C Sander; Michele M Schantz; Katherine E Sharpless; Lorna T Sniegoski; Susan S-C Tai; Jeanice B Thomas; Thomas W Vetter; Michael J Welch; Stephen A Wise; Laura J Wood; William F Guthrie; Charles R Hagwood; Stefan D Leigh; James H Yen; Nien-Fan Zhang; Madhu Chaudhary-Webb; Huiping Chen; Zia Fazili; Donna J LaVoie; Leslie F McCoy; Shahzad S Momin; Neelima Paladugula; Elizabeth C Pendergrast; Christine M Pfeiffer; Carissa D Powers; Daniel Rabinowitz; Michael E Rybak; Rosemary L Schleicher; Bridgette M H Toombs; Mary Xu; Mindy Zhang; Arthur L Castle Journal: Anal Chem Date: 2013-12-03 Impact factor: 6.986
Authors: Ida Chiara Guerrera; Giuseppe Astarita; Jean-Philippe Jais; Dorota Sands; Anna Nowakowska; Julien Colas; Isabelle Sermet-Gaudelus; Martin Schuerenberg; Daniele Piomelli; Aleksander Edelman; Mario Ollero Journal: PLoS One Date: 2009-11-06 Impact factor: 3.240
Authors: Young-Mi Go; Yongliang Liang; Karan Uppal; Quinlyn A Soltow; Daniel E L Promislow; Lynn M Wachtman; Dean P Jones Journal: PLoS One Date: 2015-11-18 Impact factor: 3.240
Authors: Xin Hu; Ki-Hye Kim; Youri Lee; Jolyn Fernandes; M Ryan Smith; Yu-Jin Jung; Michael Orr; Sang-Moo Kang; Dean P Jones; Young-Mi Go Journal: Am J Pathol Date: 2019-05-18 Impact factor: 4.307
Authors: B T Kopp; E Joseloff; D Goetz; B Ingram; S L Heltshe; D H Leung; B W Ramsey; K McCoy; D Borowitz Journal: J Cyst Fibros Date: 2018-11-23 Impact factor: 5.482
Authors: Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes Journal: Respir Med Date: 2021-11-23 Impact factor: 3.415
Authors: Zachery R Jarrell; Matthew Ryan Smith; Ki-Hye Kim; Youri Lee; Xin Hu; Xiaojia He; Michael Orr; Yan Chen; Sang-Moo Kang; Dean P Jones; Young-Mi Go Journal: Toxicol Sci Date: 2022-06-28 Impact factor: 4.109
Authors: Benjamin L Wisniewski; Chandra L Shrestha; Shuzhong Zhang; Rohan Thompson; Myron Gross; Judith A Groner; Karan Uppal; Octavio Ramilo; Asuncion Mejias; Benjamin T Kopp Journal: J Cyst Fibros Date: 2020-05-30 Impact factor: 5.482